OIG Remains Focused On Pharmaceutical Copayment Coupons

Law360, New York (October 22, 2014, 12:38 PM EDT) -- On Sept. 19, 2014, the U.S. Department of Health and Human Services' Office of Inspector General simultaneously issued a report and special advisory bulletin addressing the use of copayment coupons by pharmaceutical manufacturers to reduce or eliminate immediate out-of-pocket costs for specific prescription drugs. These releases indicate that pharmaceutical manufacturers and pharmacies may have legal exposure if copayment coupon programs are not carefully implemented and monitored to ensure the coupons are not used by patients for prescriptions covered under federal health care programs.

The OIG Office of Evaluation and Inspections report, Manufacturer Safeguards May Not Prevent Copayment Coupon Use for Part...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!